Effect of CEAG on Inflammation and Endothelial Function

Acute Effects of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG) on Inflammation and Endothelial Function

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03906825

Acronym

CEAG

Enrollment

Registered

2019-04-08

Start date

2018-05-17

Completion date

2018-08-13

Last updated

2020-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Inflammation

Keywords

Endothelium

Brief summary

The purpose of the study is to look at the effect a dietary supplement called CEAG \[Curcuminoids, EPA (Omega-3), Astaxanthin and Gamma Linolenic Acid (GLA)\] has on inflammation and endothelial (inner layer of the blood vessels) function and whether it causes a lowering of blood pressure.The endothelium plays in an important role in blood pressure.

Detailed description

This clinical trial is to assess the efficacy of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA for improving inflammation and endothelial reactivity over a four week intervention period in individuals with metabolic syndrome. The study also examines the effect of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA administration on other markers of cardiovascular function and cardiovascular disease risk including Total, LDL and HDL-Cholesterol, Triglycerides, and a multitude of inflammatory markers.

Interventions

DIETARY_SUPPLEMENTCEAG

Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA

DIETARY_SUPPLEMENTplacebo

placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Double Blind Placebo Controlled

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18-75 years * BP 121-140/81-90 mm Hg on average * Body Mass Index (BMI) 18-40.

Exclusion criteria

* free of chronic diseases including cancer or rheumatologic disorders * weight in excess of 350 pounds * bleeding disorder * history of myocardial infarction or all types of revascularization procedures, second or third degree heart block with or without a pacemaker * angina pectoris of any type * concurrent potentially life-threatening arrhythmia or symptomatic arrhythmia clinically significant valvular heart disease * history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, (with the exception of localized basal cell carcinoma of the skin) * serum creatinine \> 2.0 mg/dl * concurrent enrollment in another placebo-controlled trial.

Design outcomes

Primary

Measure	Time frame	Description
change from baseline in inflammation at 4 weeks	4 weeks	Inflammatory markers IL-6, CRP

Secondary

Measure	Time frame	Description
Rate of change from baseline of endothelial function	4 weeks	endothelial function measured by brachial artery flow mediated dilatation
Rate of change in cardio-metabolic relevant biomarkers	4 weeks	Cardio-metabolic relevant biomarkers including fasting Lipids (mg/dL), Glucose (mg/dL)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026